<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46526">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500550</url>
  </required_header>
  <id_info>
    <org_study_id>CR-AIR-008</org_study_id>
    <nct_id>NCT02500550</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor</brief_title>
  <official_title>An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiadis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiadis Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a repeat dose administration of ATIR101 is
      safe and effective when infused in patients with a hematologic malignancy following a T-cell
      depleted stem cell graft from a related haploidentical donor. All patients are planned to
      receive two ATIR101 doses of 2×10E6 viable T-cells/kg, unless the second dose is reduced or
      halted for safety reasons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CR-AIR-008 is an exploratory, open-label, multicenter study. After signing informed
      consent, patients will receive a hematopoietic stem cell transplantation (HSCT) from a
      related, haploidentical donor, followed by a first ATIR101 infusion at a dose of 2×10E6
      viable T-cells/kg between 28 and 32 days after the HSCT. Patients will receive a second
      ATIR101 infusion at a dose of 2×10E6 viable T-cells/kg between 70 and 74 days after the
      HSCT. To evaluate safety of the second dose administration, the first 6 patients treated
      will be evaluated for the occurrence of dose limiting toxicity (DLT), defined as acute GvHD
      grade III/IV within 120 days post HSCT (or within 42 days after the second ATIR101 infusion
      in case of prior dose delays). If within the first 6 patients no DLT is observed, treatment
      of the remaining 9 patients will continue with two ATIR101 doses of 2×10E6 viable T
      cells/kg. If within the first 6 patients at least 2 patients show DLT, the second ATIR101
      infusion will be adjusted to a dose of 1×10E6 viable T cells/kg. If in one of the next 3
      patients treated at this lower dose again DLT is observed, the second ATIR101 infusion will
      be halted and the remaining patients will be given only a single dose of ATIR101.

      All patients treated with ATIR101 will be followed up until 12 months after the HSCT.
      Assessments will be performed at weekly visits from the day of the first ATIR101 infusion
      (Week 4) until 6 weeks after the second ATIR101 infusion (Week 16), at monthly visits from 4
      until 6 months after the HSCT, and every 3 months from 6 until 12 months after the HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute graft versus host disease (GvHD) grade III/IV</measure>
    <time_frame>180 days post HSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GvHD</measure>
    <time_frame>12 months post HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of acute and chronic GvHD</measure>
    <time_frame>12 months post HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to T-cell reconstitution,</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as the time to CD3+ in peripheral blood higher than 0.2×10E9/L (at two consecutive measurements; time to first measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral, fungal, and bacterial infections</measure>
    <time_frame>12 months post HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of viral, fungal, and bacterial infections</measure>
    <time_frame>12 months post HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality (TRM)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as death due to causes other than disease relapse or progression, or other causes which are unrelated to the transplantation procedure (e.g. accident, suicide)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-related mortality (RRM)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as death due to disease relapse or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as the time from HSCT until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as the time from HSCT until relapse, disease progression, or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GvHD-free, relapse-free survival (GRFS)</measure>
    <time_frame>12 months post HSCT</time_frame>
    <description>Defined as the time until acute GvHD grade III/IV, chronic GvHD requiring systemic treatment, relapse, or death, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>ATIR101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATIR101</intervention_name>
    <description>T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).</description>
    <arm_group_label>ATIR101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any of the following hematologic malignancies:

               -  Acute myeloid leukemia (AML) in first remission with high-risk features or in
                  second or higher remission

               -  Acute lymphoblastic leukemia (ALL) in first remission with high-risk features or
                  in second or higher remission

               -  Myelodysplastic syndrome (MDS): transfusion-dependent, or intermediate or higher
                  IPSS-R risk group

          -  Karnofsky performance status ≥ 70%

          -  Eligible for haploidentical stem cell transplantation according to the investigator

          -  Male or female, age ≥ 18 years and ≤ 65 years

        Exclusion Criteria:

          -  Availability of a fully matched related or unrelated donor following a donor search

          -  Diffusing capacity for carbon monoxide (DLCO) &lt; 50% predicted

          -  Left ventricular ejection fraction &lt; 50% (evaluated by echocardiogram or MUGA)

          -  AST &gt; 2.5 x ULN (CTCAE grade 2)

          -  Bilirubin &gt; 1.5 x ULN (CTCAE grade 2)

          -  Creatinine clearance &lt; 50 mL/min (calculated or measured)

          -  Positive HIV test

          -  Positive pregnancy test (women of childbearing age only)

          -  Prior allogeneic HSCT

          -  Estimated probability of surviving less than 3 months

          -  Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)

          -  Known presence of HLA antibodies against the non-shared donor haplotype

          -  Any other condition which, in the opinion of the investigator, makes the patient
             ineligible for the study

        Inclusion Criteria Donor:

          -  Haploidentical family donor with 2 to 3 mismatches at the HLA-A, -B and/or -DR loci
             of the unshared haplotype

          -  Male or female, age ≥ 16 and ≤ 75 years (If applicable, local legal requirements for
             donors under the age of 18 will be followed)

          -  Eligible for donations of human blood and blood components according to local
             requirements and regulations

          -  Eligible for donation according to the transplantation center

        Exclusion Criteria Donor:

          -  Positive pregnancy test or nursing (women of childbearing age only)

          -  Positive viral test for HIV-1, HIV-2, HBV, HCV, Treponema pallidum, HTLV 1 (if
             tested), HTLV-2 (if tested), or WNV (if tested)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Claude Roy, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital (Montreal, Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Mielke, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Julius Maximilian University of Würzburg (Würzburg, Germany)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen Rovers, MD PhD</last_name>
    <phone>+31 20 3140 250</phone>
    <email>j.rovers@kiadis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Nikiforow, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Jan</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominik Selleslag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Lewalle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yves Beguin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gasthuisberg</name>
      <address>
        <city>Louvain</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johan Maertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital and Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irwin Walker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis Claude Roy, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Radovan Vrhovac, Prof MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Guenther, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Maria Wagner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Mielke, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnon Nagler, Prof MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bhuvan Kishore, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 ONN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eduardo Olavarria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 4, 2016</lastchanged_date>
  <firstreceived_date>July 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haploidentical stem cell transplantation</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>Immune reconstitution</keyword>
  <keyword>Alloreactive T-cells</keyword>
  <keyword>Photodynamic treatment</keyword>
  <keyword>Hematologic malignancy</keyword>
  <keyword>Transplant-related mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
